The increasing demand for real-time, wireless, and sustainable motion monitoring in applications such as personal health, professional sports, and human-machine interactions calls for wearable devices that are lightweight and battery free.
SAN DIEGO, Nov. 3, 2025 /PRNewswire/ — The U.S. Food and Drug Administration (“FDA”) has granted QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global leader of in vitro diagnostics, 510(k) clearance for the VITROS hs Troponin I Reagent Pack (the “VITROS hs Troponin I Assay”). The assay is intended for the quantitative measurement of cardiac troponin I (cTnI) in human plasma (heparin) to aid in the diagnosis of myocardial infarction (MI).
VANCOUVER, BC, Nov. 3, 2025 /PRNewswire/ — WAT Medical Enterprise Ltd. proudly announced the publication of a groundbreaking clinical trial in The Journal of Bone & Joint Surgery (JBJS) which demonstrates the significant benefits of the EmeTerm wristband in reducing postoperative nausea and vomiting (PONV) in patients undergoing total hip or knee arthroplasty (THA/TKA) under spinal anesthesia.
University of Texas at Dallas researchers have developed biosensor technology that, when combined with artificial intelligence (AI), shows promise for detecting lung cancer through breath analysis.
A naturally occurring gene called Cyclin A2 (CCNA2), which turns off after birth in humans, can actually make new, functioning heart cells and help the heart repair itself from injury, including a heart attack or heart failure, when the gene is turned back on.
Cornell University researchers and collaborators have developed a neural implant so small that it can rest on a grain of salt, yet it can wirelessly transmit brain activity data in a living animal for more than a year.
MIT researchers show they can use messenger RNA to activate the pathway and trigger the immune system to attack tumors.
Antibody unmasks pancreatic tumors’ ‘sugar-coated’ disguise to keep them from evading immune system
InterVene’s Recana is claimed to be the first fully integrated catheter system to address venous in-stent restenosis (ISR).
Pulsenmore announced today that it received FDA de novo clearance for its home-use prenatal ultrasound platform.